Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

The following is a summary of “Dupilumab Improves Dermatology-Specific Quality of Life in Patients with Chronic Spontaneous ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 ...

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and 2023, according to a poster presented here. “That seems to have held the test ...

Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic ...

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.